natgillin/translations-raw huggingface dataset:
Resistance During or following a course of treatment with ciprofloxacin bacteria that demonstrate resistance to ciprofloxacin may be isolated, with or without a clinically apparent superinfection.
45 Odpornost Med ali po zdravljenju s ciprofloksacinom se lahko izolirajo bakterije odporne na ciprofloksacin, z ali brez klinično izražene superinfekcije.
45 Cytochrome P450 Ciprofloxacin inhibits CYP1A2 and thus may cause increased serum concentration of concomitantly administered substances metabolised by this enzyme (e. g. theophylline, clozapine, ropinirole, tizanidine).
Citokrom P450 Ciprofloksacin zavira encimski sistem CYP1A2, kar lahko povzroči zvišanje serumskih koncentracij sočasno danih zdravil, ki se presnavljajo s pomočjo tega encima (npr. teofilin, klozapin, ropinirol, tizanidin).
Consequently, ciprofloxacin should be administered either 1-2 hours before or at least 4 hours after these preparations.
Zdravilo Ciprofloksacin je treba vzeti 1 do 2 uri pred uživanjem teh pripravkov ali vsaj 4 ure po njem.
However, the concurrent administration of dairy products or mineral-fortified drinks alone (e. g. milk, yoghurt, calcium-fortified orange juice) with ciprofloxacin should be avoided because absorption of ciprofloxacin may be reduced.
Hkratni uporabi mlečnih izdelkov ali z minerali obogatenih pijač (npr. mleko, jogurt, s kalcijem obogaten pomarančni sok) in ciprofloksacina se je treba izogibati, ker se lahko zmanjša absorpcija ciprofloksacina.
Co-administration of probenecid and ciprofloxacin increases ciprofloxacin serum concentrations.
Sočasna uporaba probenecida in ciprofloksacina zveča serumsko koncentracijo ciprofloksacina.
46 Theophylline
46 Metotreksat
During the combination, serum theophylline concentrations should be checked and the theophylline dose reduced as necessary (see section 4.4).
Med sočasno uporabo teh dveh zdravil je treba spremljati serumsko koncentracijo teofilina in če je potrebno njegov odmerek zmanjšati (glejte poglavje 4. 4).
Lactation Ciprofloxacin is excreted in breast milk.
47 Dojenje Ciprofloksacin se izloča v materino mleko.
47 4.7 Effects on ability to drive and use machines
4. 7 Vpliv na sposobnost vožnje in upravljanja s stroji
Due to its neurological effects, ciprofloxacin may affect reaction time.
Zaradi nevroloških učinkov ciprofloksacin lahko vpliva na odzivne sposobnosti.
System Organ
Organski
≥ 1/ 100
≥ 1/ 100 do
(cannot be estimated from available data)
razpoložljivih podatkov)
Infections and Infestations
kolitis, ki nastane
Mycotic superinfections
in parazitske bolezni
Antibiotic associated colitis (very rarely with possible fatal outcome) (see section 4.4)
zaradi jemanja antibiotikov (zelo redko z možnim smrtnim izidom) (glejte poglavje 4. 4)
Leukopenia Anaemia Neutropenia Leukocytosis Thrombocytopenia Thrombocytaemia
trombocitopenija trombocitemija
Allergic reaction Allergic oedema / angiooedema
edem/ angioedem
Psychiatric Disorders
Psihiatrične
Psychomotor hyperactivity / agitation
psihomotorič
Confusion and disorientation Anxiety reaction Abnormal dreams Depression Hallucinations
zmedenost in
Psychotic reactions (see section 4.4)
psihotične
48 System Organ
48
Nervous System Disorders
hiperaktivnos t / agitacija
Headache Dizziness Sleep disorders Taste disorders
anksiozna reakcija nočne more depresija halucinacije
Par- and Dysaesthesia Hypoaesthesia Tremor Seizures (see section 4.4) Vertigo
hipoestezija tremor krči (glejte poglavje 4. 4) vrtoglavica
Migraine Disturbed coordination Gait disturbance Olfactory nerve disorders Intracranial hypertension
koordinacije motnje ravnotežja motnje vohanja zvišan intrakranialni tlak
Peripheral neuropathy (see section 4.4)
(glejte poglavje 4. 4)
Eye Disorders Ear and Labyrinth Disorders
Očesne bolezni Ušesne bolezni, vključno z motnjami labirinta
Visual disturbances Tinnitus Hearing loss / Hearing impaired
motnje vida zvonjenje v ušesih oglušitev/ motnje sluha
Visual colour distortions
motnje zaznavanja barv
Ventricular arrhythmia, QT prolongation, torsades de pointes *
ventrikularne aritmije, podaljšanje intervala QT, torsade de pointes *
Vascular Disorders
vaskulitis
Vasodilatation Hypotension Syncope
pankreatitis
Vasculitis
prebavil
Respiratory, Thoracic and Mediastinal Disorders
driska
Dyspnoea (including asthmatic condition)
bolečine v trebuhu dispepsija flatulenca
Gastrointestinal Disorders
jetrna okvara
Nausea Diarrhoea
jetrna nekroza
Vomiting Gastrointestinal and abdominal pains Dyspepsia Flatulence
zvišanje
Pancreatitis
holestatski
Hepatobiliary Disorders
(zelo redko
Increase in transaminases Increased bilirubin
žolčnika in
Hepatic impairment Cholestatic icterus Hepatitis
ikterus
Liver necrosis (very rarely progressing to life-threatening hepatic failure) (see section 4.4)
napreduje v
49 System Organ
49
Skin and Subcutaneous Tissue Disorders
zvišanje vrednosti bilirubina
Rash Pruritus Urticaria
nevarno jetrno odpoved)
Photosensitivity reactions (see section 4.4)
reakcije (glejte
Petechiae Erythema multiforme Erythema nodosum Stevens- Johnson syndrome (potentially life- threatening) Toxic epidermal necrolysis (potentially life- threatening)
multiforme minor Erythema nodosum Stevens - Johnsonov sindrom (lahko smrtno nevaren) toksična epidermalna nekroliza (lahko smrtno nevarna)
Musculoskeletal, Connective Tissue and Bone Disorders
okončinah,
Musculoskeletal pain (e. g. extremity pain, back pain, chest pain) Arthralgia
hrbtu, prsnem košu)
Myalgia Arthritis Increased muscle tone and cramping
Ahilove tetive) (glejte poglavje 4. 4)
Muscular weakness Tendinitis Tendon rupture (predominantly Achilles tendon) (see section 4.4) Exacerbation of symptoms of myasthenia gravis (see section 4.4)
poslabšanje miastenije gravis (glejte poglavje 4. 4)
Renal impairment
ledvična odpoved
Renal failure Haematuria Crystalluria (see section 4.4) Tubulointerstitial nephritis
hematurija kristalurija (glejte poglavje 4. 4) tubulointersticijs ki nefritis
Asthenia Fever
telesna temperatura
Increase in blood alkaline phosphatase
vrednosti alkalne fosfataze v
Prothrombin level abnormal Increased amylase
vrednosti protrombina zvišanje
50 An overdose of 12 g has been reported to lead to mild symptoms of toxicity.
Prekomerni odmerek 12 g je povzročil blage simptome toksičnosti.
Impermeability and/ or active substance efflux pump mechanisms of resistance may have a variable effect on susceptibility to fluoroquinolones, which depends on the physiochemical properties of the various active substances within the class and the affinity of transport systems for each active substance.
Neprepustnosti in/ ali mehanizmi odpornosti, kjer gre za prenos zdravilne učinkovine iz celice z membransko črpalko, vplivata na različno občutljivost za fluorokinolone, kar je odvisno od fizikalno - kemijskih lastnosti različnih zdravilnih učinkovin znotraj skupine ter afinitete do transportnih 51 sistemov vsake posamezne zdravilne učinkovine.
Enterobacteria Pseudomonas Acinetobacter Staphylococcus spp.1
Enterobacteria Pseudomonas Acinetobacter
S ≤ 0.5 mg/ L S ≤ 0.5 mg/ L S ≤ 1 mg/ L S ≤ 1 mg/ L
1
R > 1 mg/ L R > 1 mg/ L R > 1 mg/ L R > 1 mg/ L
R > 1 mg/ l R > 1 mg/ l R > 1 mg/ l
Haemophilus influenzae and Moraxella catarrhalis
Staphylococcus spp.
S ≤ 0.5 mg/ L
S < 1 mg/ l
R > 0.5 mg/ L
R > 1 mg/ l
Neisseria gonorrhoeae Neisseria meningitidis Non-species-related breakpoints*
Haemophilus influenzae in Moraxella catarrhalis Neisseria gonorrhoeae Neisseria meningitidis *
S ≤ 0.03 mg/ L S ≤ 0.03 mg/ L S ≤ 0.5 mg/ L
S < 0, 5 mg/ l S < 0, 03 mg/ l S < 0, 03 mg/ l
R R
S < 0, 5 mg/ l
Groupings of relevant species according to ciprofloxacin susceptibility (for Streptococcus species see section 4.4) COMMONLY SUSCEPTIBLE SPECIES Aerobic Gram-positive micro-organisms Bacillus anthracis (1) Aerobic Gram-negative micro-organisms Aeromonas spp.
52 SPLOŠNO OBČULJIVE VRSTE aerobni, po Gramu pozitivni mikroorganizmi Bacillus anthracis( 1) aerobni, po Gramu negativni mikroorganizmi Aeromonas spp.
Yersinia pestis Anaerobic micro-organisms Mobiluncus Other micro-organisms Chlamydia trachomatis ($) Chlamydia pneumoniae ($) Mycoplasma hominis ($) Mycoplasma pneumoniae ($) SPECIES FOR WHICH ACQUIRED RESISTANCE MAY BE A PROBLEM Aerobic Gram-positive micro-organisms Enterococcus faecalis ($) Staphylococcus spp. *(2) Aerobic Gram-negative micro-organisms Acinetobacter baumannii+ Burkholderia cepacia+* Campylobacter spp. +* Citrobacter freundii* Enterobacter aerogenes Enterobacter cloacae* Escherichia coli* Klebsiella oxytoca
Yersinia pestis anaerobni mikroorganizmi Mobinculus drugi mikroorganizmi Chlamydia trachomatis ($) Chlamydia pneumoniae ($) Mycoplasma hominis ($) Mycoplasma pneumoniae ($) VRSTE, PRI KATERIH JE PRIDOBLJENA ODPORNOST LAHKO DVOMLJIVA aerobni, po Gramu pozitivni mikroorganizmi Enterococcus faecalis ($) Staphylococcus spp. * (2) aerobni, po Gramu negativni mikroorganizmi Acinetobacter baumannii+ Burkholderia cepacia + * Campylobacter spp. + * Citrobacter freundii * Enterobacter aerogenes Enterobacter cloacae * Escherichia coli * Klebsiella oxytoca Klebsiella pneumoniae * Morganella morganii * Neisseria gonorrhoeae * Proteus mirabilis * Proteus vulgaris * Providencia spp.
Propionibacterium acnes INHERENTLY RESISTANT ORGANISMS Aerobic Gram-positive micro-organisms Actinomyces Enteroccus faecium Listeria monocytogenes Aerobic Gram-negative micro-organisms Stenotrophomonas maltophilia Anaerobic micro-organisms Excepted as listed above Other micro-organisms Mycoplasma genitalium Ureaplasma urealitycum * Clinical efficacy has been demonstrated for susceptible isolates in approved clinical indications + Resistance rate ≥ 50% in one or more EU countries ($):
Propionibacterium acnes ODPORNI ORGANIZMI aerobni, po Gramu pozitivni mikroorganizmi Actinomyces Enteroccus faecium Listeria monocytogenes
Natural intermediate susceptibility in the absence of acquired mechanism of resistance (1):
53 aerobni, po Gramu negativni mikroorganizmi Stenotrophomonas maltophilia anaerobni mikroorganizmi razen mikroorganizmov navedenih zgoraj drugi mikroorganizmi Mycoplasma genitalium Ureaplasma urealitycum * klinično učinkovitost so dokazali pri občutljivih izolatih za odobrene klinične indikacije + stopnja odpornosti ≥ 50% v eni ali več državah Evropske unije ($) naravna vmesna občutljivost v odsotnosti pridobljene odpornosti (1):
53 Protein binding of ciprofloxacin is low (20-30%).
Ciprofloksacin se slabo veže na plazemske beljakovine (20 - 30%) in je v plazmi prisoten pretežno v neionizirani obliki.
Ciprofloxacin is known to be a moderate inhibitor of the CYP 450 1A2 iso-enzymes.
Ciprofloksacin je srednje močni zaviralec izoencimskega sistema CYP450 1A2.
Elimination
54 Izločanje
Excretion of ciprofloxacin (% of dose) Oral Administration
izločanje ciprofloksacina (% odmerka)
54 phototumorigenic effect of ciprofloxacin in-vitro and in animal experiments.
Podatki o fotomutagenosti/ fotokarcinogenosti kažejo na šibak fotomutageni ali fototumorogeni učinek ciprofloksacina in vitro in v poskusih na živalih.
In a study in young beagle dogs, ciprofloxacin caused severe articular changes at therapeutic doses after two weeks of treatment, which were still observed after 5 months.
55 ciprofloksacin v terapevtskih odmerkih, je le ta po dveh tednih zdravljenja povzročil hude spremembe v sklepih, ki so bile opazne tudi po 5 mesecih.
[To be completed nationally]
[Izpolni država članica] 56 1.
Ciprofloxacin Bayer and associated names (see Annex I) 500 mg film-coated tablets [See Annex I - To be completed nationally]
Ciprofloksacin Bayer in povezana imena (Glejte Dodatek I) 500 mg filmsko obložene tablete [Glejte Dodatek I – Izpolni država članica]
Ciprofloxacin Bayer 500 mg film-coated tablets are indicated for the treatment of the following infections (see sections 4.4 and 5.1).
Zdravilo Ciprofloksacin Bayer 500 mg filmsko obložene tablete se uporablja za zdravljenje naslednjih okužb (glejte poglavji 4. 4 in 5. 1)..
57 • Malignant external otitis
57 • okužbe kože in mehkih tkiv, ki jih povzročajo po Gramu negativne bakterije
Total duration of treatment (potentially including initial parenteral treatment with ciprofloxacin)
inhalacijski vranični prisad (zaščita in
500 mg twice daily
500 mg dvakrat na dan 59
60 days from the confirmation of Bacillus anthracis exposure
60 dni od potrjene
Children and adolescents
indikacije
Indications
dnevni odmerki (mg)
Daily dose in mg
Otroci in mladostniki
Total duration of
dnevni odmerki (mg)
Drug administration should begin as soon as possible after suspected or confirmed exposure.
inhalacijski vranični prisad (zaščita in zdravljenje po izpostavitvi povzročitelju) pri osebah, ki se lahko zdravijo peroralno, če je to klinično primerno; zdravljenje je treba začeti takoj po domnevni ali potrjeni izpostavitvi povzročitelju
10 mg/ kg body weight twice daily to 15 mg/ kg body weight twice daily with a maximum of 500 mg per dose.
do 15 mg/ kg telesne mase dvakrat na dan; največ 500 mg na odmerek
60 days from the confirmation of Bacillus anthracis exposure
60 dni po potrjeni izpostavitvi Bacillus anthracis
Other severe infections
druge hude okužbe 20
20 mg/ kg body weight twice daily with a maximum of 750 mg per dose.
mg/ kg telesne mase dvakrat na dan; največ 750 mg na odmerek
60
60 Okvarjeno delovanje ledvic in jeter
Intra-abdominal infections There are limited data on the efficacy of ciprofloxacin in the treatment of post-surgical intra-abdominal infections.
61 Intraabdominalne okužbe Podatki o učinkovitosti ciprofloksacina pri zdravljenju intraabdominalnih okužb po kirurških posegih so omejeni.
61 Travellers’ diarrhoea The choice of ciprofloxacin should take into account information on resistance to ciprofloxacin in relevant pathogens in the countries visited.
Potovalna driska Pri zdravljenju bolnikov s potovalno drisko je potrebno upoštevati podatke o odpornosti povzročiteljev na ciprofloksacin v državah, v katere so potovali.
Infections of the bones and joints Ciprofloxacin should be used in combination with other antimicrobial agents depending on the results of the microbiological documentation.
Okužbe kosti in sklepov Ciprofloksacin je treba uporabljati v kombinaciji z drugimi antibakterijskimi zdravili, odvisno od mikrobioloških izvidov.
Musculoskeletal System Ciprofloxacin should generally not be used in patients with a history of tendon disease/ disorder related to quinolone treatment.
62 Mišičnoskeletni sistem Ciprofloksacin se praviloma ne sme uporabljati pri bolnikih z boleznimi/ poškodbami kit v anamnezi, ki so bile povezane z zdravljenjem s kinoloni.
62 Tendinitis and tendon rupture (especially Achilles tendon), sometimes bilateral, may occur with ciprofloxacin, as soon as the first 48 hours of treatment.
Včasih se lahko po zdravljenju s ciprofloksacinom (v prvih 48 urah zdravljenja) pojavi tendinitis ali ruptura kite (predvsem Ahilove tetive), včasih obojestransko.
Resistance During or following a course of treatment with ciprofloxacin bacteria that demonstrate resistance to ciprofloxacin may be isolated, with or without a clinically apparent superinfection.
63 Odpornost Med ali po zdravljenju s ciprofloksacinom se lahko izolirajo bakterije odporne na ciprofloksacin, z ali brez klinično izražene superinfekcije.
63 Cytochrome P450 Ciprofloxacin inhibits CYP1A2 and thus may cause increased serum concentration of concomitantly administered substances metabolised by this enzyme (e. g. theophylline, clozapine, ropinirole, tizanidine).
Citokrom P450 Ciprofloksacin zavira encimski sistem CYP1A2, kar lahko povzroči zvišanje serumskih koncentracij sočasno danih zdravil, ki se presnavljajo s pomočjo tega encima (npr. teofilin, klozapin, ropinirol, tizanidin).
64 Theophylline
64 Metotreksat
Lactation Ciprofloxacin is excreted in breast milk.
65 Dojenje Ciprofloksacin se izloča v materino mleko.
Psychomotor hyperactivity / agitation
psihomotoričn
66 System Organ
66
Nervous System Disorders
hiperaktivnost / agitacija
Hepatic impairment Cholestatic icterus Hepatitis
žolčevodov
Liver necrosis (very rarely progressing to life-threatening hepatic failure) (see section 4.4)
nevarno jetrno
67 System Organ
67
Skin and Subcutaneous Tissue Disorders
vrednosti bilirubina
Rash Pruritus Urticaria
fotosenzitivne
Musculoskeletal pain (e. g. extremity pain, back pain, chest pain) Arthralgia
hrbtu, prsnem
Muscular weakness Tendinitis Tendon rupture (predominantly Achilles tendon) (see section 4.4) Exacerbation of symptoms of myasthenia gravis (see section 4.4)
Ahilove tetive) (glejte poglavje 4. 4) poslabšanje miastenije gravis (glejte poglavje 4. 4)
68 An overdose of 12 g has been reported to lead to mild symptoms of toxicity.
Prekomerni odmerek 12 g je povzročil blage simptome toksičnosti.
69
69 Spekter protibakterijske učinkovitosti
Haemophilus influenzae and Moraxella catarrhalis
EUCAST (The European Committee on Antimicrobial Succeptibility Testing) priporočila
S ≤ 0.5 mg/ L
občutljiva
R > 0.5 mg/ L
odporna
Neisseria gonorrhoeae Neisseria meningitidis Non-species-related breakpoints*
Enterobacteria Pseudomonas Acinetobacter Staphylococcus spp. 1 Haemophilus influenzae in Moraxella catarrhalis Neisseria gonorrhoeae Neisseria meningitidis Mejne vrednosti za nespecifične vrste *
S ≤ 0.03 mg/ L S ≤ 0.03 mg/ L S ≤ 0.5 mg/ L
S < 0, 5 mg/ l S < 0, 5 mg/ l S < 1 mg/ l S < 1 mg/ l S < 0, 5 mg/ l S < 0, 03 mg/ l S < 0, 03 mg/ l S < 0, 5 mg/ l
> 0.06 mg/ L > 0.06 mg/ L R > 1 mg/ L
R > 1 mg/ l R > 1 mg/ l R > 1 mg/ l R > 1 mg/ l R > 0, 5 mg/ l R > 0, 06 mg/ l R > 0, 06 mg/ l R > 1 mg/ l
Groupings of relevant species according to ciprofloxacin susceptibility (for Streptococcus species see section 4.4)
Specifične vrste bakterij razvrščenih glede na občutljivost za ciprofloksacin (za streptokoke glejte poglavje 4. 4).
70 COMMONLY SUSCEPTIBLE SPECIES Aerobic Gram-positive micro-organisms Bacillus anthracis (1) Aerobic Gram-negative micro-organisms Aeromonas spp.
SPLOŠNO OBČULJIVE VRSTE aerobni, po Gramu pozitivni mikroorganizmi Bacillus anthracis( 1) aerobni, po Gramu negativni mikroorganizmi Aeromonas spp.
Yersinia pestis Anaerobic micro-organisms Mobiluncus Other micro-organisms Chlamydia trachomatis ($) Chlamydia pneumoniae ($) Mycoplasma hominis ($) Mycoplasma pneumoniae ($) SPECIES FOR WHICH ACQUIRED RESISTANCE MAY BE A PROBLEM Aerobic Gram-positive micro-organisms Enterococcus faecalis ($) Staphylococcus spp. * (2) Aerobic Gram-negative micro-organisms Acinetobacter baumannii+ Burkholderia cepacia+* Campylobacter spp. +* Citrobacter freundii* Enterobacter aerogenes Enterobacter cloacae* Escherichia coli* Klebsiella oxytoca Klebsiella pneumoniae* Morganella morganii* Neisseria gonorrhoeae* Proteus mirabilis* Proteus vulgaris* Providencia spp.
70 drugi mikroorganizmi Chlamydia trachomatis ($) Chlamydia pneumoniae ($) Mycoplasma hominis ($) Mycoplasma pneumoniae ($) VRSTE, PRI KATERIH JE PRIDOBLJENA ODPORNOST LAHKO DVOMLJIVA aerobni, po Gramu pozitivni mikroorganizmi Enterococcus faecalis ($) Staphylococcus spp. * (2) aerobni, po Gramu negativni mikroorganizmi Acinetobacter baumannii+ Burkholderia cepacia + * Campylobacter spp. + * Citrobacter freundii * Enterobacter aerogenes Enterobacter cloacae * Escherichia coli * Klebsiella oxytoca Klebsiella pneumoniae * Morganella morganii * Neisseria gonorrhoeae * Proteus mirabilis * Proteus vulgaris * Providencia spp.
Propionibacterium acnes INHERENTLY RESISTANT ORGANISMS Aerobic Gram-positive micro-organisms Actinomyces Enteroccus faecium Listeria monocytogenes
Propionibacterium acnes ODPORNI ORGANIZMI aerobni, po Gramu pozitivni mikroorganizmi Actinomyces Enteroccus faecium Listeria monocytogenes aerobni, po Gramu negativni mikroorganizmi Stenotrophomonas maltophilia anaerobni mikroorganizmi razen mikroorganizmov navedenih zgoraj drugi mikroorganizmi Mycoplasma genitalium Ureaplasma urealitycum
71 Aerobic Gram-negative micro-organisms Stenotrophomonas maltophilia Anaerobic micro-organisms Excepted as listed above Other micro-organisms Mycoplasma genitalium Ureaplasma urealitycum * Clinical efficacy has been demonstrated for susceptible isolates in approved clinical indications + Resistance rate ≥ 50% in one or more EU countries ($):
71 * klinično učinkovitost so dokazali pri občutljivih izolatih za odobrene klinične indikacije + stopnja odpornosti ≥ 50% v eni ali več državah Evropske unije ($) naravna vmesna občutljivost v odsotnosti pridobljene odpornosti (1):
72 Ciprofloxacin is largely excreted unchanged both renally and, to a smaller extent, faecally.
72 izločanje ciprofloksacina (% odmerka)
Excretion of ciprofloxacin (% of dose) Oral Administration
peroralna uporaba
6.1 List of excipients
73 6. 1 Seznam pomožnih snovi
73 6.2 Incompatibilities
6. 2 Inkompatibilnosti
[To be completed nationally]
[Izpolni država članica] 6. 3 Rok uporabnosti
74 1.
74 1.
Ciprofloxacin Bayer and associated names (see Annex I) 750 mg film-coated tablets [See Annex I - To be completed nationally]
Ciprofloksacin Bayer in povezana imena (Glejte Dodatek I) 750 mg filmsko obložene tablete [Glejte Dodatek I – Izpolni država članica]
Ciprofloxacin Bayer 750 mg film-coated tablets are indicated for the treatment of the following infections (see sections 4.4 and 5.1).
Zdravilo Ciprofloksacin Bayer 750 mg filmsko obložene tablete se uporablja za zdravljenje naslednjih okužb (glejte poglavji 4. 4 in 5. 1)..
75 • Malignant external otitis
75 • okužbe kože in mehkih tkiv, ki jih povzročajo po Gramu negativne bakterije
Gonococcal uretritis and cervicitis
za fluorokinolone občutljiv gonokokni uretritis in cervicitis
Diarrhoea caused by bacterial pathogens including Shigella spp. other than Shigella dysenteriae type 1 and empirical treatment of severe travellers' diarrhoea
driska, ki jo povzročajo bakterije, tudi iz vrste Shigella spp., ne pa Shigella dysenteriae tipa 1 in empirično zdravljenje hude potovalne driske
Infections of the skin and soft tissue
okužbe kože in mehkih tkiv
500 mg as a single dose
500 mg enkrat na dan 77
77
dan (enkraten odmerek)
78
78 Okvarjeno delovanje ledvic in jeter
30-60
30 – 60 < 60
79 Travellers’ diarrhoea The choice of ciprofloxacin should take into account information on resistance to ciprofloxacin in relevant pathogens in the countries visited.
79 Potovalna driska Pri zdravljenju bolnikov s potovalno drisko je potrebno upoštevati podatke o odpornosti povzročiteljev na ciprofloksacin v državah, v katere so potovali.
Nevertheless, in very rare instances, after microbiological documentation of the causative organism and evaluation of the risk/ benefit balance, ciprofloxacin may be prescribed to these patients for the treatment of certain severe infections, particularly in the event of failure of the standard therapy or bacterial resistance, where the microbiological data may justify the use of ciprofloxacin.
V zelo redkih primerih, glede na mikrobiološke izvide o povzročiteljih in oceni tveganja in koristi, se lahko ciprofloksacin predpiše tudi tem bolnikom za 80 zdravljenje posebno hudih okužb, predvsem če je bilo standardno zdravljenje neuspešno ali odpornost bakterije opravičuje uporabo ciprofloksacina.
80 Tendinitis and tendon rupture (especially Achilles tendon), sometimes bilateral, may occur with ciprofloxacin, as soon as the first 48 hours of treatment.
Včasih se lahko po zdravljenju s ciprofloksacinom (v prvih 48 urah zdravljenja) pojavi tendinitis ali ruptura kite (predvsem Ahilove tetive), včasih obojestransko.
Resistance During or following a course of treatment with ciprofloxacin bacteria that demonstrate resistance to ciprofloxacin may be isolated, with or without a clinically apparent superinfection.
81 Odpornost Med ali po zdravljenju s ciprofloksacinom se lahko izolirajo bakterije odporne na ciprofloksacin, z ali brez klinično izražene superinfekcije.
81 Cytochrome P450 Ciprofloxacin inhibits CYP1A2 and thus may cause increased serum concentration of concomitantly administered substances metabolised by this enzyme (e. g. theophylline, clozapine, ropinirole, tizanidine).
Citokrom P450 Ciprofloksacin zavira encimski sistem CYP1A2, kar lahko povzroči zvišanje serumskih koncentracij sočasno danih zdravil, ki se presnavljajo s pomočjo tega encima (npr. teofilin, klozapin, ropinirol, tizanidin).
82 Theophylline
82 Metotreksat
. Simultaneous administration of ciprofloxacin with warfarin may augment its anti-coagulant effects.
Sočasna uporaba ciprofloksacina in varfarina lahko zveča antikoagulacijski učinek varfarina.